Lyell Immunopharma Inc (LYEL)

Lyell Immunopharma, Inc. is a clinical-stage biotechnology company focused on developing cell therapies for patients with hematologic malignancies and solid tumors. Its pipeline includes rondecabtagene autoleucel, an autologous dual-targeting CD19/CD20 CAR T-cell therapy being studied in pivotal PiNACLE work in the 3L+ setting and in a Phase 1/2 trial in the 2L setting, as well as the PiNACLE-H2H Phase 3 head-to-head randomized trial in large B-cell lymphoma. The company is also advancing LYL273, a GCC-targeted CAR T-cell candidate with added CD19 CAR expression and controlled cytokine release, which is in Phase 1 development for refractory metastatic colorectal cancer. Lyell also applies several cell-engineering approaches, including c-Jun overexpression, NR4A3 gene knockout, Epi-R, and CD62L-positive enrichment, to improve CAR T-cell performance. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

Jump directly to the stock analysis sections supported by the latest available data.